Literature DB >> 29158711

Chemometric evaluation of the efficacy of locally administered chlorhexidine in patients with periodontal disease.

Liljana Bogdanovska1, Ana Poceva Panovska1, Mirjana Popovska2, Aneta Dimitrovska1, Rumenka Petkovska1.   

Abstract

The process of assessment of drug efficacy produces multivariate data which are difficult to interpret. The interpretation and extraction of relevant data requires application of chemometric algorithms for multivariate data analysis. The aim of our study was evaluation of the efficacy of local treatment with chlorhexidine (CHX) in patients suffering from periodontal disease by chemometric algorithms for multivariate data analysis. Several algorithms were used: principal component analysis (PCA), partial least squares discriminant analysis (PLS-DA) and orthogonal projection to latent structures discriminant analysis (OPLS-DA). The PCA models identified the examined variables as suitable for monitoring the periodontal disease progression at the same time revealing mutual relationship among them. The developed PLS-DA model successfully distinguished patients treated with CHX from non-treated patients. The OPLS-DA model revealed differences in the mechanism of action of the two widely applied treatments in periodontal disease, local administration of CHX and local administration of doxycycline (DOX). The approach presented in this study opens the possibility of application of chemometric algorithms for multivariate data analysis for assessment of treatment efficacy.

Entities:  

Keywords:  ALP, alkaline phosphatase; AST, aspartate aminotransferase; CAL, clinical attachment loss; CHX, chlorhexidine; Chemometric algorithms; Chlorhexidine; DOX, doxycycline; GCF, gingival crevicular fluid; GI, index of gingival inflammation; IL-1β, interleukin -1 beta; LDH, lactate dehydrogenase; Multivariate data analysis; OPLS-DA, orthogonal projection to latent structures discriminant analysis; PCA, principal component analysis; PD, pocket depth; PLS-DA, partial least square discriminant analysis; Periodontal disease; TNF, α- tumor necrosis factor-alpha; Treatment efficacy; VIP, variable influence on projection

Year:  2017        PMID: 29158711      PMCID: PMC5681301          DOI: 10.1016/j.jsps.2017.03.006

Source DB:  PubMed          Journal:  Saudi Pharm J        ISSN: 1319-0164            Impact factor:   4.330


Introduction

The process of drug efficacy assessment encompasses conduction of large controlled clinical trials where relatively homogenous group of subjects are carefully evaluated with respect to predefined clinical and laboratory parameters and closely monitored with respect to unexpected effects (Rasmussen et al., 2010, Ren et al., 2012, Cleophas and Zwinderman, 2013). The massive amounts of data generated by these trials are traditionally analyzed using univariate approach i.e. considering mean result versus control (Liland, 2011, Cleophas and Zwinderman, 2013). However, the univariate approach suffers from several disadvantages such as the need for large number of samples as well as the inability to compensate for the missing data points which may require important observations to be discarded from analysis (Helmy et al., 2012). Compared to the univariate approach, the multivariate approach that uses chemometric algorithms for data analysis represents a powerful tool for exploring large datasets derived from biological systems which contain multiple variables, missing data points or relatively small number of observations (Eriksson et al., 2006, Helmy et al., 2012). Their application provides “multicomponent insight” into treatment effects and therefore the adoption of chemometric algorithms for multivariate data analysis for assessment of treatment efficacy is highly recommendable (Durcekova et al., 2011, Mocak, 2012, Jimenez et al., 2013, Mrazova et al., 2014). Periodontal disease is an inflammatory condition initiated by a bacterial infection which affects the supporting structures of the teeth. The treatment for periodontal disease is known as scaling and root planning and is followed by local administration of antiseptics or antibiotics. The treatment effects can be assessed by: (a) determination of clinical indices: index of gingival inflammation (GI), periodontal pocket depth (PD) or clinical attachment loss (CAL); (b) determination of inflammatory biomarkers in gingival crevicular fluid (GCF), (enzymes alkaline phosphatase (ALP), aspartate aminotransferase (AST), lactate dehydrogenase (LDH)) or cytokines (interleukin - 1β (IL-1β) and tumor necrosis factor - α (TNF-α)) and (c) determination of concentration of the applied drug in GCF (Perinneti et al., 2008, Aimetti et al., 2012, Ertugrul et al., 2013, Spruill et al., 2014). However, the conclusions regarding treatment efficacy are commonly derived using the conventional approach. The biggest drawback of the univariate approach in dentistry is multicollinearity – mathematical coupling of variables which may lead to greater uncertainty in the result and may require removal of certain variables. One of the possible solutions to the problem lies in the application of chemometric algorithms for multivariate data analysis such as principal component analysis, partial least square regression or extension of these algorithms (Tu et al., 2009). In our study, we will assess the performance of chemometric algorithms for multivariate data analysis for evaluation of efficacy of local administration of chlorhexidine (CHX) in patients suffering from periodontal disease. Furthermore, the efficacy of local administration of CHX is compared to the efficacy of local administration of doxycycline (DOX), another commonly used drug in periodontal treatment.

Materials and methods

Chemicals and materials

Chlorhexidine digluconate and chlorpheniramine maleate (internal standard, IS) were purchased from Sigma Aldrich (Germany) and Supriya Lifescience Ltd. (India), respectively. HPLC grade methanol and acetonitrile (ACN) were supplied by Carlo Erba (Italy). Sodium phosphate, triethylamine (TEA) and phosphoric acid (p.a grade) were also purchased from Sigma Aldrich (Germany). Throughout the entire chromatographic analysis, HPLC water was used. Whatman 3MM chromatography paper strips, 2 × 5 mm (Whatman Lab sales Ltd., UK) were used for GCF collection. Chlorhexamed 1% gel (0.5 g chlorhexidine digluconate/50 g gel) was purchased from GlaxoSmithCline, GmbH, Buehl, Germany while ATRIDOX 10% gel (45 mg doxycycline hyclate/0.5 g gel) was supplied by TOLMAR Inc. Fort Collins (USA). Protease inhibitor cocktail for cytokine determination was purchased from Sigma Aldrich (Germany). The assay kits for ALP, LDH and AST activity determination were purchased from Biosystems (Spain). The concentration levels of IL-1β and TNF-α in GCF samples were analyzed using commercial ELISA kits (Booster Immunoleader, Fremont, CA).

Subjects and protocol

The subjects who participated in the study were divided in three groups: experimental group of 34 patients who received local treatment with CHX gel (conventional release gel formulation), experimental group of 25 patients who received local treatment with DOX gel (controlled release gel formulation) and a control group of 9 healthy volunteers, with no previous history of periodontal disease. All patients were recruited from the Department of Periodontology, Faculty of Dentistry in Skopje. The study protocol was approved by the Ethics Committee at the Faculty of Dentistry and all the patients provided written informed consent before attending the study.

GCF sample collection

GCF samples were collected from quadrants consisting of five periodontal pockets before and after the local periodontal treatment. The patients who received the local treatment with CHX were administered 330 mg of gel containing 2 mg of CHX and GCF samples were taken 30 min after the gel application. The patients treated with DOX gel were administered 115 mg gel containing 10 mg of DOX and the GCF samples were taken 7 days after the local treatment. GCF from the selected periodontal pockets was collected using the method proposed by Koss et al. In brief, the paper strips were placed in selected periodontal pockets until mild resistance was felt and left in place for 30 s (Koss et al., 2009).

Chromatographic conditions for determination of CHX in GCF samples

The HPLC analysis was conducted on Shimadzu Nexera HPLC system with UV diode array detector. The chromatographic separation was achieved using Discovery C18 chromatographic column, 250 × 4.6 mm, 5 μm (Supelco, USA) at 25 °C. The mobile phase consisted of ACN, 0.01 mol L−1 phosphate buffer adjusted to pH = 3.0 using phosphoric acid and TEA (33: 66:1, V/V/V). The mobile phase flow rate was set at 1 mL/min and the injection volume was 50 μL. The wavelength of detection was 253 nm and the total runtime for the analysis was 10 min. The method was validated according to EMA Guideline on bioanalytical method validation (EMA, 2011).

Measurement of clinical indices

The degree of periodontal inflammation/health was assessed by the following clinical indices: pocket depth (PD), clinical attachment level (CAL) and index of gingival inflammation (GI). The indices were recorded by a single examiner, before and after local administration of CHX and DOX. GI was expressed using values from 1 to 3, where value of 1 expresses low inflammation and the value of 3 means high inflammation. PD and CAL were measured in mm. PD value larger than 3 mm indicates existence of periodontal pockets and CAL value larger than 3 indicates periodontal disease.

Determination of inflammatory biomarkers in GCF samples

For determination of inflammatory biomarker activity/concentration in GCF, the total of five paper strips were placed in 500 μL PBS (phosphate buffer saline, pH = 7.4) and the tube was centrifuged for 5 min at 1000 × g (4 °C) in a microcentrifuge (Centurion Scientific K3 Series) to elute the GCF component. The solutions containing the GCF component were divided in two aliquots of 250 μL. The aliquot for determination of enzyme activity was assayed immediately after collection whereas the aliquot for determination of cytokine concentration was added proteinase inhibitor cocktail and kept at −80 °C until analysis. ALP, LDH and AST activity in GCF sample solutions were determined using semiautomatic photometer (HymaLizer Primus, Germany). The determination was performed using commercial kits according to the International Federation of Clinical Chemistry (IFCC) recommendations. The final results were expressed as total enzyme activity per sample (IU/sample). The concentration levels of IL-1β and TNF-α in GCF sample solutions were analyzed using commercial ELISA kits, according to manufacturer’s instructions. The absorbance was measured by spectrophotometric ELISA reader (Viktor X3, Perkin Elmer). The total amounts of IL-1β and TNF-α were expressed as pg mL−1. The analyses were performed in duplicate.

Chemometric algorithms for multivariate data analysis

Data preprocessing

Prior application of chemometric algorithms, the obtained results were organized in tables (Microsoft Office Excel 2003) where the patients were inserted into rows and the examined variables were positioned in columns. The measured variables were: ALP, AST and LDH activity, IL-1β and TNF-α concentration in GCF samples before and after local administration of CHX; clinical indices: GI, PD and CAL before and after local administration of CHX, as well as CHX concentration in GCF after the local administration. Data unit-to variance (UV) scaling was performed in order to remove systematic differences among variables due to difference in measurement units and then a logarithmic transformation to each variable was applied.

Chemometric algorithms

Chemometric algorithms for multivariate data analysis: principal component analysis (PCA), partial least squares discriminant analysis (PLS-DA) and orthogonal projection to latent structures-discriminant analysis (OPLS-DA) were applied to the data sets using SIMCA 13.0.3 software (Umetrics, Umea, Sweden). PCA is an unsupervised algorithm which performs orthogonal linear transformation of possibly correlated variables into smaller number uncorrelated variables called principal components (PCs). PCA converts data into score plots which are visual representations of the studied samples and enables preliminary investigation of the variability in the data set, correlations among the studied variables and identification of outliers. Next, PLS-DA, algorithm that uses class information to maximize separation between classes, was applied for supervised classification and discrimination between classes of data obtained before and after local administration of CHX. To avoid model overfitting, the obtained PLS-DA model was validated by default 7-round cross-validation with 1/7 of the samples being excluded from the model in each round, as well as 20 times permutation testing. At the final stage, OPLS-DA was used to find the differences and improve separation between classes obtained after local administration of CHX and after local administration of DOX. PLS-DA and OPLS-DA model performance was evaluated using coefficients R2 and Q2, both of which vary between 0 and 1 (Eriksson et al., 2006). R2 (goodness of fit) provides an indication of the extent to which a variation within a data set can be explained by the various components of the model. The value for Q2 is more important since it indicates how accurately data, either classes or non-classed can be predicted by the model. A Q2 value > 0.5 indicates a good model. To identify variations responsible for separation between classes, the corresponding variable influence on projection (VIP) for the PLS-DA and OPLS-DA model were carefully inspected since they represent the measure of the degree to which a particular variable explains Y variance (class membership in our case).

Univariate data analysis

The statistical significance of the differences between the mean of the discriminating variables as identified from the VIP plot of the OPLS-DA model, was assessed by the non-parametric Mann-Whitney U test using SPSS 17 software. A P value < 0.05 (95% confidence level) was considered statistically significant.

Results and discussion

CHX is an antiseptic widely used in the treatment of periodontal disease. It shows broad spectrum of topical antimicrobial activity, suitable effectiveness and lack of toxicity (Paolantonio et al., 2008). The local delivery of CHX gel in periodontal pockets enhances the effect of scaling and root planning, thus CHX gel application shows long lasting (up to 90 days) favorable effects (Perinneti et al., 2004).

Chemometric evaluation of CHX treatment efficacy using multivariate data analysis

PCA

The first step of the chemometric evaluation of treatment efficacy was application of the PCA algorithm to the data set containing results from the control group of patients (Table 1) and periodontal patients before and after the local administration of CHX (Table 2).
Table 1

Results from determination of inflammatory biomarkers in GCF samples and clinical indices in the control group.

aALP (IU/L)LDH (IU/L)AST (IU/L)IL-1β (pg mL−1)TNF-α (pg mL−1)GIbCAL (mm)PD (mm)
137.3263.126.727.335.6222
224.9251.06.731.215.6111
37.389.510.015.612.4121
414.936.426.717.418.0111
529.799.513.331.218.7121
627.3111.013.315.620.4111
729.6384.916.717.421.8111
817.699.920.035.918.5111
919.0389.616.729.015.6111

N°- number of GCF samples from the control group.

GI – expressed as values ranging from 1 дo 3.

Table 2

Results from determination of inflammatory biomarkers in GCF samples and clinical indices in periodontal patients before and after local administration of CHX.


Results obtained before the local CHX treatment
Results obtained after the local CHX treatment
N12345678N12345678a
149.8267.115.0191.426.33533522.1437.148.3214.125.9123
258.0518.133.3448.233.22443616.3342.230.78.520.1123
353.9769.098.3445.925.22453729.028.3200.08.525.9123
426.3445.236.7465.322.62333841.581.028.3623.833.4123
538.7534.336.7332.930.11653931.8388.680.0129.749.9132
642.8854.081.7416.336.31544055.31447.455.0172.445.6123
756.7740.725.0356.324.22434169.01094.055.0408.345.9233
859.41376.261.7167.542.92544227.6696.2106.773.621.6223
953.9902.6115153.329.92544336.8562.433.3114.421.6142
1047.0967.453.3103.218.93534434.21461.141.7166.528.6242
1148.4765.050.0143.238.22424532.8611.226.7131.230.6122
1253.91024.133.3125.432.92344648.4789.356.7300.320.4244
1347.0655.713.379.640.92454729.3627.544.2173.735.6222
1472.61255.964.9261.443.12444825.4459.354.4200.428.9234
1580.0455.998.4146.146.32454920.1168.324.2145.725.9123
1639.5955.471.9407.250.92335016.3336.729.0220.020.1123
1745.61000.765.4294.563.13655120.0459.331.7204.525.9123
1845.61432.955.3228.431.03545231.5498.728.6178.333.4123
1975.0851.439.0322.330.02435331.5627.524.6322.349.9132
2078.6669.343.0461.725.42325438.4269.239.2359.633.4111
2162.4422.047.0271.437.32545556.2437.152.4171.245.6123
2265.6536.935.9309.841.02435626.6342.253.7309.745.9233
2371.4991.040.7204.044.12545722.428.323.7178.621.6223
2476.3887.975.4125.040.33545834.281.035.7125.021.6142
2543.6731.870.2181.926.02425942.8388.620.6157.928.6242
2653.9602.045.0168.729.72346038.4157.948.3129.030.6122
2778.9731.737.9300.324.12456142.81447.430.7225.320.4244
2861.0376.746.7287.733.73656229.31094.026.7257.326.9132
2965.4920.557.5259.727.53436325.4696.228.3173.729.0121
3055.5554.945.4146.133.13246429.0874.980.0103.725.1222
3137.3263.126.7274.435.62226522.1437.148.3214.125.9123
3224.9250.96.731.215.61116616.3342.230.78.520.1123
3327.3263.126.7274.435.62226729.028.3200.08.525.9123
3431.8473.631.7507.328.92346841.581.028.3623.833.4123

1- ALP activity (IU/L); 2-LDH activity (IU/L); 3- AST activity (IU/L); 4 - IL-1β concentration (pg mL−1); 5 - TNF-α concentration (pg mL−1); 6- GI index (1–3); 7-CAL (mm); 8-PD (mm).

Results from determination of inflammatory biomarkers in GCF samples and clinical indices in the control group. N°- number of GCF samples from the control group. GI – expressed as values ranging from 1 дo 3. Results from determination of inflammatory biomarkers in GCF samples and clinical indices in periodontal patients before and after local administration of CHX. 1- ALP activity (IU/L); 2-LDH activity (IU/L); 3- AST activity (IU/L); 4 - IL-1β concentration (pg mL−1); 5 - TNF-α concentration (pg mL−1); 6- GI index (1–3); 7-CAL (mm); 8-PD (mm). The aim of performing PCA was to extract the most important information from the data set and analyze the structure of the observations and the variables. PCA reveals natural grouping of the studied observations (periodontal patients) and the selected variables in a reduced dimensional space. The first principal component (PC1) and further PCs are linear combinations of the original variables, which still preserve maximal variance of the data. Usually, the first two PCs contain most of the variance of the data, whereas the other PCs are unimportant (Cordella, 2012). The results from the application of the PCA algorithm on the data set of the control group vs. diseased patients are shown in Fig. 1.
Fig. 1

Score plots of PCA model of data set from the control group of volunteers and periodontal patients before local administration of CHX (Hotteling’s ellipse). (A) Identification of outliers by the PCA model (B) PCA model after exclusion of outliers, the left cluster of points belongs to the control group (C), the right cluster to periodontitis patients before local administration of CHX.

Score plots of PCA model of data set from the control group of volunteers and periodontal patients before local administration of CHX (Hotteling’s ellipse). (A) Identification of outliers by the PCA model (B) PCA model after exclusion of outliers, the left cluster of points belongs to the control group (C), the right cluster to periodontitis patients before local administration of CHX. The inspection of the Hoteling’s ellipse of the PCA model reveals that the control group is positioned in a tight cluster in the negative parts of the PC1 axe, whereas the periodontitis patients before local administration of CHX are located at high PC1 values. The discrimination of the data in two groups obtained by the PCA model demonstrates that selected clinical indices and inflammatory biomarkers can be used to monitor the progression of periodontal disease. PC1 accounts for 60.9% and PC2 accounts for 8.86% of the total variance of the data, or together the first two principal components explain around 70% of the data variability. Further inspection of the loading plots of the same PCA model (Fig. 2) was made in order to examine the relative contribution of each of the selected variables to the two principal components.
Fig. 2

Loading plot for PC1 and PC2 showing variables that enable discrimination between control group of and periodontal patients before administration of CHX.

Loading plot for PC1 and PC2 showing variables that enable discrimination between control group of and periodontal patients before administration of CHX. Four of the selected biomarkers (ALP, AST, LDH and TNF-α) and the clinical indices are located at the positive values of PC1 axe, with ALP, PD and CAL located at the PC2 axe, but also very close to the PC1. This finding suggests that a GCF sample from a patient located at the positive PC1 values indicates not only elevated levels of inflammatory biomarkers but also elevated values for the clinical indices. However, the PCA model did not discriminate between inflammatory biomarkers and clinical indices as distinct groups of parameters for monitoring periodontal disease progression. In the next step, we aimed to examine applicability of the PCA algorithm for monitoring the therapeutic effects of local administration of CHX based on changes of the selected inflammatory biomarkers and the clinical indices, before and after treatment. The PCA model of resulted only in partial separation, with only 50% of the variability in the data being explained (Fig. 3).
Fig. 3

PCA model of patient’s data taken before and after the local administration of CHX. The score plot shows the model’s inability for data discrimination.

PCA model of patient’s data taken before and after the local administration of CHX. The score plot shows the model’s inability for data discrimination. However, the correlation matrix for the selected variables was inspected in order to explore their relationships. The results from this kind of analysis are presented in the form of correlation table, containing the calculated pair (Pearson) correlation coefficient, indicator of the strength of correlation between all pairs of variables. The importance of the correlation is evaluated against the critical value of the sample correlation coefficient, r = 0.250. This value depends on the number of degrees of freedom (number of samples minus two) and the selected probability (usually p < 0.05). The significant correlations are bolded (Table 3).
Table 3

Correlation coefficients among selected variables in patients before and after local administration of CHX. Significant correlations are bolded.

ALPLDHASTIL-1βTNF-αGICALPD
ALP1.0000.3780.2690.1690.3040.4890.5390.439
LDH1.0000.348−0.0280.1700.2810.3410.267
AST1.000−0.0150.2220.1920.1960.233
IL-1β1.0000.0850.0520.1380.148
TNF-α1.0000.1220.1750.137
GI1.0000.5020.438
CAL1.0000.592
PD1.000
Correlation coefficients among selected variables in patients before and after local administration of CHX. Significant correlations are bolded. The correlation table revealed significant correlations between ALP activity and the clinical indices, GI, CAL and PD before and after local administration of CHX. Considering the fact that the first two principal components of the model insufficiently explained the data variability, application of different chemometric algorithms for multivariate data analysis was needed.

PLS-DA

The next step consisted of analysis of the data before and after the local administration of CHX using the PLS-DA algorithm. PLS-DA is a regression extension of the principal component analysis that uses class information to maximize the separation between various groups of observations (Helmy et al., 2012). A drug’s efficacy is related to its concentration at the site of action (GCF in our case), so in this step the variable concentration of CHX in GCF after local administration was included in order to assess treatment efficacy. In order to quantify CHX concentrations in GCF samples after gel application we developed, optimized and validated a RP - HPLC method with UV detection for determination of CHX in GCF. The results from the validation have been published in our previous paper (Bogdanovska et al., 2014). The concentrations of CHX in GCF samples after the local administration are presented in Table 4 and a representative chromatogram of a patient’s GCF sample after the local treatment is shown in Fig. 4.
Table 4

CHX concentrations in patient’s GCF samples after the local treatment.

Patient N°CHX (µg mL−1)Patient N°CHX (µg mL−1)
1154.1218135.39
2122.0519187.84
3133.0720156.96
4135.3921126.05
5167.8422122.92
6156.9623164.39
7136.0524145.36
8164.3925139.82
9139.8226149.82
10139.8227126.79
11126.7928135.21
12130.2129137.82
13147.8230159.25
14169.2531100.36
15174.1232112.69
16125.0533135.39
17123.0734187.24
Fig. 4

Representative chromatogram of a patient’s GCF sample after the local administration of CHX (1-chlorpheniramine (internal standard), 2-CHX).

Representative chromatogram of a patient’s GCF sample after the local administration of CHX (1-chlorpheniramine (internal standard), 2-CHX). CHX concentrations in patient’s GCF samples after the local treatment. The score plot of the three component PLS-DA model showed clear separation between data before and after local administration of CHX, as shown in Fig. 5.
Fig. 5

PLS-DA score plot of data (GCF inflammatory biomarkers, clinical indices and CHX concentration in GCF) before and after the local administration of CHX. Squares clustered to left represent data before treatment, whereas squares clustered to the right represent data after treatment with CHX.

PLS-DA score plot of data (GCF inflammatory biomarkers, clinical indices and CHX concentration in GCF) before and after the local administration of CHX. Squares clustered to left represent data before treatment, whereas squares clustered to the right represent data after treatment with CHX. The data before local administration of CHX clustered to the left part of the score plot, whereas data after local administration of CHX clustered to the right. This model provided good group separation, with R2X (cum) value of 0.572, R2Y (cum) = 0.894 and Q2Y (cum) = 0.823, which indicates potent statistical model according to the cross-validation. Further confirmation of no overfitting in the obtained PLS-DA model was made by permutation testing. Permutation testing provides the statistical significance of the estimated predictive power of the model by comparing the R2Y and Q2Y values of the original model with those of the reordered model, created by random permutation of y – data. Models with R2Y intercept < 0.4 and Q2Y intercept < 0.05 indicate valid models. As shown in Fig. 6, the PLS-DA model had R2Y intercept of 0.0743 and Q2Y intercept of −0.361, indicating there is no overfitting.
Fig. 6

Validation of the PLS-DA model using permutation testing. Each symbol represents a permutation result, R2 is represented by green squares and Q2 by blue squares.

Validation of the PLS-DA model using permutation testing. Each symbol represents a permutation result, R2 is represented by green squares and Q2 by blue squares. The most important variables accountable for the separation between the classes were extracted using the VIP statistics (variable influence on projection) of the PLS-DA model. VIP statistics ranks the overall contribution of each variable to the generation of the model and points out most significant variables. It is generally accepted that a VIP value between 0.8 and 1.2 yields relevant variables (Chong and Jun, 2005). According to the VIP criterion, three examined variables in the model (AST, IL-1β and TNF-α) did not influence separation significantly. The rest of the variables showed significant influence on the separation in classes, with change in CHX concentration after treatment being the most significant. The PLS-DA model identified the change in ALP activity after treatment as second most important variable for class separation suggesting that ALP activity may be used in assessment of treatment efficacy. At the same time, as revealed by the VIP plot, the treatment induced small changes on the studied cytokines which might be due to the antibacterial mechanism of action of CHX (see Fig. 7).
Fig. 7

VIP statistics plot of the X-variables of the three component PLS-DA model for efficacy evaluation of local administration of CHX.

VIP statistics plot of the X-variables of the three component PLS-DA model for efficacy evaluation of local administration of CHX.

OPLS-DA

The final step in our study consisted of comparison between effects of local administration of CHX and local administration of DOX, commonly applied drugs in the periodontal treatment, with distinct mechanism of action. The results from determination of inflammatory biomarkers and clinical indices after local administration of DOX are presented in Table 5. In order to understand the differences, a sophisticated chemometric algorithm, OPLS-DA, was applied on the data sets containing results after local treatment with CHX and after local treatment with DOX.
Table 5

Results from determination of inflammatory biomarkers in GCF samples and clinical indices in periodontal patients after the local treatment with DOX.

12345678a
141.5226.78.315.621.9122
216.6137.620.033.623.3111
36.9668.816.724.022.9111
422.1741.616.789.029.0111
518.0429.016.755.415.6122
638.7416.916.762.523.7111
724.953.32.331.87.8111
827.6315.77.842.217.7122
942.8267.115.0162.022.9111
1052.51003.173.337.619.6123
1138.7505.956.795.530.6132
1219.31044.325.0146.835.2132
1334.61291.235.0136.415.6231
1431.81894.9103.356.935.6122
1552.5918.870.047.823.2123
1633.2323.816.7221.833.9142
1766.31076.230.0301.442.9131
1824.9344.056.7156.415.6121
1916.0429.016.7125.415.6122
2035.7416.916.762.523.7123
2120.9789.328.331.87.8142
2221.7315.77.8221.817.7131
2338.7267.115.0162.022.9121
2452.5283.173.3137.619.6132
2538.7505.956.795.530.6222

1- ALP activity (IU/L); 2-LDH activity (IU/L); 3- AST activity (IU/L); 4 - IL-1β concentration (pg mL-1); 5 - TNF-α concentration (pg mL-1); 6- GI index (1–3); 7-CAL (mm); 8-PD (mm).

Results from determination of inflammatory biomarkers in GCF samples and clinical indices in periodontal patients after the local treatment with DOX. 1- ALP activity (IU/L); 2-LDH activity (IU/L); 3- AST activity (IU/L); 4 - IL-1β concentration (pg mL-1); 5 - TNF-α concentration (pg mL-1); 6- GI index (1–3); 7-CAL (mm); 8-PD (mm). The OPLS-DA algorithm is a modification of the traditional PLS-DA algorithm with integral orthogonal signal correction filter (Wiklund et al., 2008, Smilde et al., 2010). The separation of Y-predictive (discriminating variation) and Y-orthogonal variation (variation not contributing to class separation) yields in better interpretability of the data, especially in cases where subtle differences among classes are present. Thus, in this study, OPLS – DA was used to extract statistically significant variables responsible for class separation using the VIP statistics of the model. As it can be seen from the score plot (Fig. 8), the OPLS-DA model divided samples from the two treatment groups in different clusters. According to the results from cross-validation of the model, R2X (cum) = 0.527, R2Y (cum) = 0.507 and Q2X (cum) = 0.530, indicating a good model.
Fig. 8

Score plot of the OPLS-DA model of data obtained after the local administration of CHX and after local administration of DOX in periodontal patients.

Score plot of the OPLS-DA model of data obtained after the local administration of CHX and after local administration of DOX in periodontal patients. The VIP statistics, as with the PLS-DA model, was used to identify variables which differ significantly between both treatment groups. The VIP statistics plot is shown in Fig. 9. As it can be seen from the VIP plot, four examined variables contributed significantly for separation between treatment groups (PD, AST, IL-1β and TNF-α).
Fig. 9

VIP statistics plot of the X-variables of the OPLS-DA model for comparative evaluation of efficacy of local administration of CHX and local administration of DOX.

VIP statistics plot of the X-variables of the OPLS-DA model for comparative evaluation of efficacy of local administration of CHX and local administration of DOX. In order to get confirmation for the statistical significance of the identified differences, we used non-parametric Mann Whitney U test, as the data were not normally distributed. Compared to the local administration of CHX, the local administration of DOX resulted in greater decrease of AST activity and cytokine concentration (p < 0.05) which might be due to the anti-inflammatory action of DOX and its ability to stabilize cell membranes, thus decreasing the intacytoplasmic activity of enzymes such as AST.

Conclusion

In this study, we performed chemometric evaluation of the efficacy of local administration of CHX in patients with periodontal disease. The PCA models showed that the selected inflammatory biomarkers and clinical indices can be used for monitoring periodontal disease progression due to their discriminative power. Although, the PCA algorithm could not identify changes as a result of CHX administration, the PLS-DA model successfully classified data before and after local administration of CHX and identified the most influential variables responsible for class separation. The comparison of efficacy of local administration of CHX and local administration of DOX using the OPLS-DA algorithm identified differences in treatment effects thus providing insights into mechanisms of action of the two treatments. In summary, the application of chemometric algorithms for multivariate data analysis (PCA, PLS-DA and OPLS-DA) may provide useful approach for evaluation of treatment efficacy.
  12 in total

1.  Dynamic metabolomic data analysis: a tutorial review.

Authors:  A K Smilde; J A Westerhuis; H C J Hoefsloot; S Bijlsma; C M Rubingh; D J Vis; R H Jellema; H Pijl; F Roelfsema; J van der Greef
Journal:  Metabolomics       Date:  2009-12-04       Impact factor: 4.290

2.  Visualization of GC/TOF-MS-based metabolomics data for identification of biochemically interesting compounds using OPLS class models.

Authors:  Susanne Wiklund; Erik Johansson; Lina Sjöström; Ewa J Mellerowicz; Ulf Edlund; John P Shockcor; Johan Gottfries; Thomas Moritz; Johan Trygg
Journal:  Anal Chem       Date:  2007-11-21       Impact factor: 6.986

3.  Partial least squares path modelling for relations between baseline factors and treatment outcomes in periodontal regeneration.

Authors:  Yu-Kang Tu; Mark S Gilthorpe; Francesco D' Aiuto; Andrew Woolston; Valerie Clerehugh
Journal:  J Clin Periodontol       Date:  2009-10-06       Impact factor: 8.728

4.  Comparison of CCL28, interleukin-8, interleukin-1β and tumor necrosis factor-alpha in subjects with gingivitis, chronic periodontitis and generalized aggressive periodontitis.

Authors:  A S Ertugrul; H Sahin; A Dikilitas; N Alpaslan; A Bozoglan
Journal:  J Periodontal Res       Date:  2012-07-19       Impact factor: 4.419

5.  Multivariate evaluation of pharmacological responses in early clinical trials - a study of rIL-21 in the treatment of patients with metastatic melanoma.

Authors:  Morten Arendt Rasmussen; Morten Colding-Jørgensen; Lasse Tengbjerg Hansen; Rasmus Bro
Journal:  Br J Clin Pharmacol       Date:  2010-04       Impact factor: 4.335

6.  Effect of the statin therapy on biochemical laboratory tests--a chemometrics study.

Authors:  Tatiana Durceková; Ján Mocák; Katarína Boronová; Ján Balla
Journal:  J Pharm Biomed Anal       Date:  2010-08-06       Impact factor: 3.935

7.  Gingival crevicular fluid alkaline phosphatase activity reflects periodontal healing/recurrent inflammation phases in chronic periodontitis patients.

Authors:  Giuseppe Perinetti; Michele Paolantonio; Beatrice Femminella; Emanuela Serra; Giuseppe Spoto
Journal:  J Periodontol       Date:  2008-07       Impact factor: 6.993

8.  Clinical and microbiological effects of subgingival administration of two active gels on persistent pockets of chronic periodontitis patients.

Authors:  Giuseppe Perinetti; Michele Paolantonio; Chiara Cordella; Simonetta D'Ercole; Emanuela Serra; Raffaele Piccolomini
Journal:  J Clin Periodontol       Date:  2004-04       Impact factor: 8.728

9.  Clinical and microbiologic effects of subgingival controlled-release delivery of chlorhexidine chip in the treatment of periodontitis: a multicenter study.

Authors:  Michele Paolantonio; Matteo D'Angelo; Roberto Felice Grassi; Giuseppe Perinetti; Raffaele Piccolomini; Giuseppe Pizzo; Marco Annunziata; Domenico D'Archivio; Simonetta D'Ercole; Gianna Nardi; Luigi Guida
Journal:  J Periodontol       Date:  2008-02       Impact factor: 6.993

10.  Multivariate evaluation of the effectiveness of treatment efficacy of cypermethrin against sea lice (Lepeophtheirus salmonis) in Atlantic salmon (Salmo salar).

Authors:  Daniel F Jimenez; Crawford W Revie; Simon P Hardy; Peder A Jansen; George Gettinby
Journal:  BMC Vet Res       Date:  2013-12-20       Impact factor: 2.741

View more
  1 in total

1.  Metabonomics study on the hepatoprotective effect mechanism of polysaccharides from different processed products of Angelica sinensis on layer chickens based on UPLC-Q/TOF-MS/MS, multivariate statistical analysis and conjoint analysis.

Authors:  Fan-Lin Wu; Yong-Hao Hu; Peng Ji; Chen-Chen Li; Jian He
Journal:  Biomed Chromatogr       Date:  2022-04-26       Impact factor: 1.911

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.